CD34 and ovarian carcinoma: In this study, we primarily used CD34+ HPC-derived NK cells that have already been shown to be able to efficiently kill ovarian cancer cells in vitro and in vivo (46), and these cells are currently tested in a phase I study in EOC patients (NCT03539406).